Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: A phase I/II trial of the AGO study group

导出原文传递

翻译打印收藏纠错

作者： DuBois,A. ^[1] ; Vergote,I. ^[2] ; Wimberger,P. ^[3] ; Ray-Coquard,I. ^[4] ; Harter,P. ^[5] ; Curtis,L.B. ^[6] ; Mitrica,I.

作者单位： GlaxoSmithKline, Brentford, London, United Kingdom ^[1] Departments of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Henricistrasse 92, 45136 ^[2] GlaxoSmithKline, Research Triangle Park, NC, United States ^[3] Centre Leon Bérard, Lyon, France ^[4] Department of Gynecologic Oncology, University Hospitals Leuven, Leuven, Belgium ^[5] Department of Gynecology and Obstetrics, University of Duisburg-Essen, Essen, Germany ^[6]

关键词 ovarian cancer pazopanib phase I study

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

The British journal of cancer

2012年106卷4期

629-632页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: A phase I/II trial of the AGO study group

The British journal of cancer

相似文献

The British journal of cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: A phase I/II trial of the AGO study group

The British journal of cancer

相似文献

The British journal of cancer

相关期刊

检索历史清除